Ascendis Pharma A/S (ASND)
120.97
-1.83
(-1.49%)
USD |
NASDAQ |
May 17, 16:00
120.97
0.00 (0.00%)
After-Hours: 20:00
Ascendis Pharma EPS Diluted (Quarterly): -2.498 for March 31, 2024
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -2.498 |
| December 31, 2023 | -1.658 |
| September 30, 2023 | -3.136 |
| June 30, 2023 | -2.355 |
| March 31, 2023 | -2.127 |
| December 31, 2022 | -3.783 |
| September 30, 2022 | -3.052 |
| June 30, 2022 | -1.555 |
| March 31, 2022 | -2.480 |
| December 31, 2021 | -2.139 |
| September 30, 2021 | -1.733 |
| June 30, 2021 | -3.013 |
| March 31, 2021 | -1.410 |
| December 31, 2020 | -3.148 |
| September 30, 2020 | -2.701 |
| June 30, 2020 | -2.170 |
| March 31, 2020 | -1.457 |
| December 31, 2019 | -1.882 |
| September 30, 2019 | -0.5893 |
| June 30, 2019 | -1.404 |
| March 31, 2019 | -1.409 |
| Date | Value |
|---|---|
| December 31, 2018 | -0.8671 |
| September 30, 2018 | -0.9418 |
| June 30, 2018 | -0.6567 |
| March 31, 2018 | -1.314 |
| December 31, 2017 | -1.083 |
| September 30, 2017 | -1.223 |
| June 30, 2017 | -1.034 |
| March 31, 2017 | -0.8309 |
| December 31, 2016 | -0.5502 |
| September 30, 2016 | -0.8036 |
| June 30, 2016 | -0.5988 |
| March 31, 2016 | -0.9046 |
| December 31, 2015 | -0.5361 |
| September 30, 2015 | -0.3334 |
| June 30, 2015 | -0.6962 |
| March 31, 2015 | 0.0677 |
| December 31, 2014 | -0.3715 |
| September 30, 2014 | -0.1549 |
| June 30, 2014 | -0.2715 |
| March 31, 2014 | -0.0637 |
| December 31, 2013 | 0.2841 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-3.783
Minimum
Dec 2022
-0.5893
Maximum
Sep 2019
-2.215
Average
-2.154
Median
EPS Diluted (Quarterly) Benchmarks
| Evaxion Biotech AS | -1.50 |
| Biodexa Pharmaceuticals Plc | -- |
| TC BioPharm (Holdings) PLC | -- |
| Genmab A/S | 0.2939 |
| NuCana PLC | -4.657 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -142.33M |
| Revenue (Quarterly) | 104.16M |
| Total Expenses (Quarterly) | 157.54M |
| Enterprise Value | 7.294B |
| Gross Profit Margin (Quarterly) | 92.11% |
| Profit Margin (Quarterly) | -136.6% |
| Earnings Yield | -7.97% |
| Normalized Earnings Yield | -7.965 |